Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

268.80
+1.520.57%
Post-market: 276.007.20+2.68%18:24 EST
Volume:403.02K
Turnover:108.50M
Market Cap:6.72B
PE:-20.80
High:274.35
Open:263.98
Low:263.84
Close:267.28
52wk High:278.44
52wk Low:26.70
Shares:25.01M
Float Shares:19.79M
Volume Ratio:0.30
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.9227
EPS(LYR):-10.2095
ROE:-75.20%
ROA:-45.09%
PB:19.57
PE(LYR):-26.33

Loading ...

Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating

MT Newswires Live
·
Dec 12

Praxis Precision Medicines - to File a Nda for Relutrigine in Scn2a and Scn8a Dees in Early 2026

THOMSON REUTERS
·
Dec 12

Praxis Precision Medicines Reports Relutrigine Shows Significant Seizure Reduction in EMBOLD Study

Reuters
·
Dec 11

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

GlobeNewswire
·
Dec 11

BRIEF-Praxis Precision Medicines Announces Alignment With FDA

Reuters
·
Dec 10

Praxis Precision Medicines Inc: FDA Agreed to Proposed Changes to Embrave3 Trial Design to Be a Single-Arm, Baseline-Controlled Study

THOMSON REUTERS
·
Dec 10

Praxis Precision Medicines Announces Alignment With FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset Scn2a Developmental and Epileptic Encephalopathy

THOMSON REUTERS
·
Dec 10

Praxis Precision Medicines Inc: Topline Results From Ongoing Embrave Study (Part a, N=9) Expected in 1H 2026

THOMSON REUTERS
·
Dec 10

Praxis Precision Medicines Converts EMBRAVE3 Trial to Single-Arm Study for Elsunersen in SCN2A-DEE

Reuters
·
Dec 10

Praxis Precision Medicines (PRAX) Is Up 34.4% After Dual Neurology Milestones - Has The Bull Case Changed?

Simply Wall St.
·
Dec 09

Praxis Precision Medicines Inc: Monotherapy Study, Power3, Is on Track to Begin in First Half of 2026

THOMSON REUTERS
·
Dec 09

Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating

MT Newswires Live
·
Dec 08

Praxis Precision Medicines Reports 53% Seizure Reduction With Relutrigine in EMBOLD Study

Reuters
·
Dec 08

Praxis Precision Medicines Inc : Needham Raises Target Price to $315 From $304

THOMSON REUTERS
·
Dec 08

Praxis Precision Med Is Maintained at Buy by BTIG

Dow Jones
·
Dec 08

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06

Top Midday Gainers

MT Newswires Live
·
Dec 06

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Benzinga
·
Dec 06

Global Equities Roundup: Market Talk

Dow Jones
·
Dec 06

BUZZ-U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana

Reuters
·
Dec 05